CYP2C9 *2 with related variant rs1799853

Clinical Annotations

Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below. Please follow the link in the "Position" column for more information about a particular variant. Each link in the "Position" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

View the full haplotype translation table for CYP2C9

Variant Alelle
CYP2C9 121A>G
CYP2C9 146A>G
CYP2C9 208G>C
CYP2C9 226G>A
CYP2C9 287G>C
CYP2C9 293G>T
CYP2C9 329T>C
CYP2C9 356A>G
CYP2C9 370C>T
CYP2C9 389C>G
rs1799853 T (differs from reference)
CYP2C9 445G>A
CYP2C9 449G>T
CYP2C9 488C>T
CYP2C9 610A>C
CYP2C9 620T>C
CYP2C9 641A>T
CYP2C9 664A>G
CYP2C9 679C>T
CYP2C9 850A>G
CYP2C9 896C>G
CYP2C9 949C>T
CYP2C9 1004G>A
CYP2C9 1029C>A
CYP2C9 1060G>A (may also have *2 430C>T)
CYP2C9 1081C>A
CYP2C9 1144C>T
CYP2C9 1159A>G
CYP2C9 1362G>C
CYP2C9 1429G>A
CYP2C9 1468G>T
CYP2C9 1009C>A

Haplotype Annotations

PharmGKB haplotype annotations provide information about haplotype-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.

Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.

There are direct annotations for this haplotype. Register or sign in to see them.

VIP Annotation

CYP2C9*2 is defined by the 144Arg>Cys SNP. Variant frequencies are 10-20% for Caucasian populations while considerably less in the African (0-6%) and Asian (1-3%) populations. The variant was first described by Rettie et al [Article:8004131] as having impaired the ability to metabolize warfarin. It is also thought to alter the interaction with NADPH cytochrome P450 oxidoreductase [Article:9241660].

Drugs / Other Molecules